DOP2011000166A - Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, su preparacion y uso terapeutico - Google Patents

Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, su preparacion y uso terapeutico

Info

Publication number
DOP2011000166A
DOP2011000166A DO2011000166A DO2011000166A DOP2011000166A DO P2011000166 A DOP2011000166 A DO P2011000166A DO 2011000166 A DO2011000166 A DO 2011000166A DO 2011000166 A DO2011000166 A DO 2011000166A DO P2011000166 A DOP2011000166 A DO P2011000166A
Authority
DO
Dominican Republic
Prior art keywords
preparation
tetrahidropiran
pirrolidinona
piperidinona
espiro
Prior art date
Application number
DO2011000166A
Other languages
English (en)
Spanish (es)
Inventor
David Stefany
Zhongli Gao
Ryan Hartung
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of DOP2011000166A publication Critical patent/DOP2011000166A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DO2011000166A 2008-12-05 2011-06-01 Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, su preparacion y uso terapeutico DOP2011000166A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12008708P 2008-12-05 2008-12-05
FR0955909 2009-08-28

Publications (1)

Publication Number Publication Date
DOP2011000166A true DOP2011000166A (es) 2011-10-31

Family

ID=41665099

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2011000166A DOP2011000166A (es) 2008-12-05 2011-06-01 Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, su preparacion y uso terapeutico

Country Status (27)

Country Link
US (2) US8217052B2 (fr)
EP (1) EP2373659B1 (fr)
JP (1) JP5410544B2 (fr)
KR (1) KR101682889B1 (fr)
CN (1) CN102239170B (fr)
AR (1) AR074467A1 (fr)
AU (1) AU2009322243B2 (fr)
CA (1) CA2745715C (fr)
CO (1) CO6390059A2 (fr)
CR (1) CR20110289A (fr)
DO (1) DOP2011000166A (fr)
EC (1) ECSP11011109A (fr)
ES (1) ES2507574T3 (fr)
HN (1) HN2011001487A (fr)
IL (1) IL213292A (fr)
MA (1) MA32945B1 (fr)
MX (1) MX2011004791A (fr)
MY (1) MY150789A (fr)
NZ (1) NZ593150A (fr)
PA (1) PA8852301A1 (fr)
PE (1) PE20110773A1 (fr)
RU (1) RU2519778C2 (fr)
TN (1) TN2011000223A1 (fr)
TW (1) TWI441826B (fr)
UA (1) UA104880C2 (fr)
WO (1) WO2010065798A1 (fr)
ZA (1) ZA201103261B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074466A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.
JP2013526530A (ja) * 2010-05-11 2013-06-24 サノフイ 置換されたn−フェニルスピロラクタムビピロリジン、その製造及び治療上の使用
AR081908A1 (es) 2010-05-11 2012-10-31 Sanofi Aventis N-heteroaril-espirolactama-bipirrolidinas sustituidas, preparacion y usos terapeuticos de las mismas
TW201206939A (en) 2010-05-11 2012-02-16 Sanofi Aventis Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof
AR081034A1 (es) 2010-05-11 2012-05-30 Sanofi Aventis Derivados de n-heteroaril tetrahidro-isoquinolina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades del sistema nervioso central
EP2569294B1 (fr) 2010-05-11 2015-03-11 Sanofi Bipyrrolidine carboxamides n-heteroaromatiques, leur preparation et usage therapeutique
JP5766278B2 (ja) 2010-05-11 2015-08-19 サノフイ 置換されたn−アルキルおよびn−アシルテトラヒドロ−イソキノリン誘導体、それらの製造および治療上の使用
WO2011143161A1 (fr) 2010-05-11 2011-11-17 Sanofi Dérivés de n-hétérocycloalkyl-bipyrrolidinylphénylamide substitués, préparation et utilisation thérapeutique de ceux-ci

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3256276A (en) * 1961-02-17 1966-06-14 Geschickter Fund Med Res Substituted spiroimides
US3258276A (en) 1964-04-06 1966-06-28 Charles E Murcott Utility chair
WO2003031432A1 (fr) * 2001-10-12 2003-04-17 Novo Nordisk A/S Nouvelles piperidines substituees
US6889262B1 (en) 2002-06-26 2005-05-03 Advanced Micro Devices, Inc. Direct transaction mode for peripheral devices
US7279491B2 (en) 2002-10-23 2007-10-09 Janssen Pharmaceutica N.V. Phenylpiperidines and phenylpyrrolidines
US7223788B2 (en) 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
WO2005028438A1 (fr) * 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Nouveau derive de piperidine
EP2322506A1 (fr) * 2005-07-01 2011-05-18 Eli Lilly and Company Agents recepteurs de l'histamine H3, preparation et utilisations therapeutiques
RU2428423C2 (ru) * 2005-11-10 2011-09-10 Баниу Фармасьютикал Ко., Лтд. Азазамещенные спиропроизводные
BRPI0619985A2 (pt) 2005-12-16 2011-10-25 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas, métodos para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, de obesidade e de diabetes do tipo ii em um ser humano ou animal e usos dos compostos
US20080247964A1 (en) * 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
CA2653062A1 (fr) * 2006-05-23 2007-11-29 Transtech Pharma, Inc. Nouveaux medicaments
EP2049473A2 (fr) 2006-06-29 2009-04-22 Janssen Pharmaceutica N.V. Composés de benzylamine substituée
US20100317679A1 (en) 2007-09-21 2010-12-16 Ligand Pharmaceuticals, Inc. Substituted aryl-fused spirocyclic amines
EP2205558B1 (fr) 2007-10-17 2012-07-25 Sanofi Amides de n-phényl-pyrrolidinylméthylpyrrolidine substitués et leur utilisation thérapeutique comme modulateurs du récepteur h3 de l'histamine
DK2212283T3 (da) 2007-10-17 2011-12-19 Sanofi Sa Substituerede N-phenylbipyrrolidincarboxamider og terapeutisk anvendelse deraf
SI2212282T1 (sl) 2007-10-17 2012-01-31 Sanofi Sa Substituirani n-fenil-bipirolidin karboksamidi in njihova terapevtska uporaba
AR074466A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.

Also Published As

Publication number Publication date
US8217052B2 (en) 2012-07-10
CR20110289A (es) 2011-09-21
MX2011004791A (es) 2011-05-30
IL213292A (en) 2014-01-30
TW201033219A (en) 2010-09-16
US8383814B2 (en) 2013-02-26
RU2011127382A (ru) 2013-01-10
CN102239170B (zh) 2014-08-20
KR20110095911A (ko) 2011-08-25
CN102239170A (zh) 2011-11-09
AR074467A1 (es) 2011-01-19
PA8852301A1 (es) 2010-07-27
US20110251225A1 (en) 2011-10-13
WO2010065798A1 (fr) 2010-06-10
CA2745715A1 (fr) 2010-06-10
JP2012511011A (ja) 2012-05-17
EP2373659B1 (fr) 2014-07-30
ES2507574T3 (es) 2014-10-15
ECSP11011109A (es) 2011-11-30
PE20110773A1 (es) 2011-10-26
IL213292A0 (en) 2011-07-31
JP5410544B2 (ja) 2014-02-05
AU2009322243B2 (en) 2015-07-16
EP2373659A1 (fr) 2011-10-12
TWI441826B (zh) 2014-06-21
MY150789A (en) 2014-02-28
TN2011000223A1 (en) 2012-12-17
RU2519778C2 (ru) 2014-06-20
KR101682889B1 (ko) 2016-12-06
HN2011001487A (es) 2013-12-02
CO6390059A2 (es) 2012-02-29
MA32945B1 (fr) 2012-01-02
CA2745715C (fr) 2014-01-28
ZA201103261B (en) 2012-01-25
UA104880C2 (uk) 2014-03-25
NZ593150A (en) 2012-10-26
US20120238757A1 (en) 2012-09-20
AU2009322243A1 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
ECSP11011108A (es) Piperidina espiro pirrolidinona y piperidinona sustituidas, su preparación y su uso terapéutico
ECSP11011109A (es) Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, su preparación y su uso terapéutico
CY1112083T1 (el) Υποκαθιστουμενα ν-φαινυλο-διπυρρολιδινο καρβοξαμιδια και η θεραπευτικη τους χρηση
CO6190616A2 (es) Carboxamidas n-fenil-bipirrolidina sustituidas y su uso terapeutico
CY1112391T1 (el) Υποκατεστημενες ν-φαινυλ-διπυρρολιδινη ουριες και θεραπευτικες χρησεις αυτων
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
MX2010004003A (es) N-fenil-pirrolidinilmetlipirrolidin amidas sustituidas y uso terapeutico de las mismas.
CR9734A (es) Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6
CR9733A (es) Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
CR10474A (es) Derivados de benzozazol y benzotiazol como ligandos de 5-hidroxitriptamina-6
UY32294A (es) Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, su preparación y su uso terapéutico
NI201100090A (es) Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, su preparación y su uso terapéutico.
NI201100094A (es) Piperidina espiro pirrolidinona y piperidinona sustituidas, su preparación y su uso terapéutico.
CR10339A (es) Derivados de sulfonil-3-heterociclilindazol como ligandos de 5-hidroxitriptamina-6
UY30526A1 (es) Imidazolina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso